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Virus-like particles
Virus‑like particles (VLPs) are empty multiprotein 
structures closely resembling natural virions. Due to 
the absence of the genetic material, VLPs are repli‑
cation‑ and infection‑incompetent. They are formed 
spontaneously by the self‑assembly of viral proteins 
during infection or by in vitro protein expression, 
usually in a eukaryotic system. Therefore, VLPs can be 
classified depending on the original virus taxonomy 
(e.g., adenovirus, coronavirus, etc.) or depending on 
the synthesis method (e.g., animal, yeast, plant, or cell‑
free expression). Another classification of VLPs relies 
on their architecture and distinguishes enveloped and 
non‑enveloped VLPs, as well as native or chimeric 
VLPs. Non‑enveloped VLPs are typically composed 
of one or more viral structural proteins, whereas envel‑
oped VLPs consist of the host cell membrane with 
viral proteins displayed on the outer surface (Fig. 1) 
(Kushnir et al., 2012). Non‑enveloped VLPs are easier 
to produce and purify, but enveloped VLPs are more 
flexible, as antigens from different pathogens can be 
integrated. However, they may also contain host’s 
proteins, which may affect downstream applications 
(Buonaguro et al., 2011).
Expression systems
Animal cells are the most convenient expression 
system for virus‑like particles because of their ability 
to carry out the complex post‑translational modifica‑
tions that are required for proper protein folding. Genes 
encoding viral proteins of interest are introduced into 
the host cell by plasmid transfection or viral transduc‑
tion (using retroviruses, lentiviruses, adenoviruses, or 
adeno‑associated viruses for mammalian cells, or bacu‑
loviruses for insect cells). Depending on the method 
used, the transgene is integrated into the genome or 
replicates in an episomal form. The expressed viral 
proteins spontaneously self‑assemble within the cell, 
as during viral infection. Mammalian (CHO, BHK, 
HEK‑293T, COS‑11 and Vero), avian (ELL‑0) and 
insect (Lepidoptera: Spodoptera frugiperda and Tricho­
plusia ni) cells have been used for VLPs production 
in animal expression systems (Kushnir, et al., 2012). 
Examples of VLPs produced in animal cells and other 
expression systems are provided in Table I. Despite the 
fact that enveloped and non‑enveloped, native and chi‑
meric VLPs are efficiently formed in mammalian cells, 
this expression system has some limitations, including 
high production costs, potential safety concerns, and 
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difficulties with scaling up production. By contrast, 
insect cell expression system offers significant advan‑
tages for VLPs production. Not only is this system less 
expensive, but it is also easier to scale up and can be 
used for the simultaneous expression of many pro‑
teins, facilitating the assembly of VLPs (Liu et al., 2013, 
Rychlowska et al., 2011). Furthermore, insect cells have 
the ability to post‑translationally process and modify 
the recombinant proteins, similarly to their mammalian 
counterparts. Lastly, insect cells can be cultured without 
supplements derived from mammalian organisms, and 
therefore the risk of contaminating of VLPs developed 
for human therapy with opportunistic pathogens is 
minimal (Roy and Noad, 2008). Importantly, baculo‑
viruses infect only a small group of Lepidoptera and 
represent no threat to humans.
Yeast cells are a well‑established system for the 
expression of recombinant proteins. It is, however, 
important to remember that this system has some 
drawbacks that are worth considering. Yeast cells dif‑
fer from mammalian cells in their post‑translational 
modification of expressed proteins, particularly pro‑
tein glycosylation pattern. For this reason, yeast is used 
mostly for the production of non‑enveloped VLPs. 
However, a number of studies have demonstrated suc‑
cessful self‑assembly of VLPs in Pichia pastoris or Sac­
charomyces cerevisiae cells, and two popular vaccines 
licensed worldwide; against hepatitis B virus (HBV) and 
human papilloma virus (HPV) are based on VLPs pro‑
duced in yeast. Interestingly, VLPs formation of HBV 
proteins has never been observed in yeast cells, but it 
is presumed that self‑assembly takes place during the 
processing of the yeast biomass (Lünsdorf et al., 2011).
Plant expression systems represent another option 
for VLP synthesis that is cost‑effective, scalable, and 
free of mammalian pathogens. Expression of recombi‑
nant proteins in plants can be achieved either via stable 
or transient transfection of the transgene into the cell. 
Both enveloped and non‑enveloped, as well as native 
and chimeric, plant‑produced VLPs have progressed 
into clinical development (Scotti and Rybicki, 2013). 
Interestingly, plant viral vectors used for transforma‑
tion such as Tobacco mosaic virus (TMV), Alfalfa 
mosaic virus (A1MV), Cowpea mosaic virus (CPMV), 
and Papaya mosaic virus (PapMV) may incorporate 
recombinant proteins (even if these are not of viral 
origin) to form chimeric VLPs. This strategy has been 
used to obtain prophylactic vaccine candidates against 
viruses HBV, influenza virus, respiratory syncytial virus 
(RSV), Norwalk virus (NV), bacteria (Staphylococcus 
aureus, Pseudomonas aeruginosa, Bacillus anthracis, and 
Yersinia pestis) and protozoa (Plasmodium falciparum) 
Fig. 1. Schematic representation of the formation of non‑enveloped and enveloped VLPs.
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(Table I). Cultured cells originating from Nicotiana ben­
thamina and N. tabaccum are widely used plant cells to 
generate VLPs (Scotti and Rybicki, 2013). 
Bacteria, the most widely used expression system for 
recombinant proteins are not the host cell of choice for 
VLPs synthesis, due to the absence of post‑translational 
modifications, imperfect disulfide bond formation, and 
problems with solubility (Zeltins, 2013). Nevertheless, 
bacteria are used to produce non‑enveloped VLPs, 
often by means of a recombinant bacteriophage with 
Mammalian
CHO: HBsAg NE (Soulié et al., 1991)
BHK: Hantaan E (Betenbaugh et al., 1995)
Vero: Influenza E (Barrett et al., 2009)
COS‑1 DENV E (Chang et al., 2003)
HEK: Ebola E (Yamayoshi and Kawaoka, 2007)
 Marburg E (Kolesnikova et al., 2004)
 Chikungunya E (Akahata et al., 2010)
Avian
Fibroblasts ELL‑0: Nipah‑NDV E (McGinnes et al., 2010)
Insect
Spodoptera frugiperda: Influenza E (Pushko et al., 2005)
 RSV‑Influenza M1 protein* E (Quan et al., 2011)
 HIV NE (Gheysen et al., 1989)
 NV NE (El‑Kamary et al., 2010)
 RV E (Zeng et al., 1994)
 HCV E (Baumert et al., 1998)
Trichoplusia ni: HPV NE (Harper et al., 2004)
 HEV NE (Li et al., 2000)
Plant
Nicotiana tabacum: HBV (HBcAg) NE (Pniewski, 2012)
 HIV NE (Rosales‑Mendoza et al., 2012)
 Bacillus anthracis‑CPMV* NE (Phelps, et al., 2007)
Nicotiana benthamina Influenza – TMV* NE (Petukhova et al., 2014)
 Rabies – A1MV* NE (Yusibov et al., 2002)
 FMDV – TMV* NE (Wu et al., 2003)
Arabidopsis thaliana HIV/HBV (HBsAg)* NE (Greco et al., 2007)
Yeast
Pichia pastoris HBV (HBsAg) NE (Lünsdorf, et al., 2011)
 NV NE (Tomé‑Amat et al., 2014)
 HCV E (Acosta‑Rivero et al., 2001)
 DENV (Dengue virus) E (Tang et al., 2012)
Saccharomyces cerevisiae: HPV NE (Woo et al., 2008)
 HIV NE (Sakuragi et al., 2002)
  RV E (Rodríguez‑Limas et al., 2011)
Hensuela polymorpha: HBV (HBsAg) NE (Seo et al., 2008)
Bacteria
Escherichia coli: HCV‑PapMV* NE (Denis et al., 2007)
 P. falciparum‑HBcAg* NE (Sällberg et al., 2002)
Lactobacillus casei: HPV NE (Aires, et al., 2006)
Table I
Different expression systems for diverse virus‑like particles. Chimeric VLPs are denoted with an asterix*;
the exterior protein is in the first position and the scaffold protein in the second. 
Expression system VLP E/NE Reference
E – enveloped,  NE – non‑enveloped.
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foreign epitopes fused to surface proteins (Tissot et al., 
2010). Another strategy relies on prokaryotic expres‑
sion of viral protein in the form of insoluble inclusion 
bodies, followed by purification under denaturing con‑
ditions, refolding, and in vitro self‑assembly (Sánchez‑
Rodríguez et al., 2012). Even though E. coli remains the 
most commonly used bacterial host for VLP produc‑
tion, some groups have successfully produced VLPs 
in Lactobacillus (Aires et al., 2006) and Pseudomonas 
(Phelps et al., 2007) host species.
VLPs may also be formed by proteins produced in 
cell‑free expression systems and assembled in vitro. 
Further modification of this approach is to incorpo‑
rate expressed proteins into virosomes, which are also 
categorized as VLPs by some authors. Virosomes, 
defined as synthetic lipid or polypeptide scaffoldings 
decorated with viral antigens, were evaluated as vaccine 
candidates as early as in the 1970s (Almeida et al., 1975, 
Morein et al., 1979). Two examples of licensed human 
virosome vaccines are Epaxal and Inflexal, which are 
used for hepatitis A and influenza prophylaxis, respec‑
tively. The critical change in virosome production is 
that currently proteins of interest are expressed in a sys‑
tem of choice and then incorporated into a liposome 
or other carrier. Initially, viral antigens originated from 
infectious viruses, which were inactivated, dissociated, 
and fractionated before processing. 
Applications
VLPs have a broad range of potential applications 
due to the diversity and multigenicity of viruses. As 
shown with the examples provided above, these parti‑
cles may be formulated not only of proteins originating 
from one virus species, but also of proteins from unre‑
lated viruses or even different pathogens, i.e., bacteria 
and protozoa. Chimeric VLPs are of special interest as 
highly specific nanovectors for the delivery of antigens 
or therapeutic molecules.
VLPs as vaccines
Due to their virus‑like appearance and repetitive 
surface structure, VLPs show high immunogenicity 
and antigenicity. Importantly, they interact with the 
immune system similarly to their parental pathogens, 
inducing not only humoral but also cellular response, 
which is not common for traditional, subunit vac‑
cines. B cell activation and the production of high anti‑
body titers have been shown to be dependent on the 
conformation and epitope abundance of symmetric 
VLPs (Buonaguro et al., 2011). Moreover, VLPs, as exo‑ 
 genous antigens, are efficiently taken up by professional 
antigen‑presenting cells (APC), particularly dendritic 
cells (DC), which is followed by antigen processing 
and presentation by MHC class II molecules, leading 
to stimulation of CD4+ T helper cells. On the other 
hand, VLPs, similarly to native viruses, are also pro‑
cessed in the cytosol of DC as endogenous antigens 
and presented by MHC class I molecules to cytotoxic 
CD 8+ T cells (CTLs) (Grgacic and Anderson, 2006, 
Groothuis and Neefjes, 2005). This cross‑presentation 
mechanism ensures comprehensive and strong immu‑
nological responses. Additionally, numerous VLP vac‑
cines candidates are known to possess “self‑adjuvant” 
properties, probably due to their particulate structure 
and small size of (~100 nm), which favors uptake 
by APC (Keller et al., 2010, Manolova et al., 2008). 
Potentially phasing‑out adjuvants in VLPs vaccine 
formulations is unquestionably beneficial as it would 
both simplify the production process and increase the 
safety of the vaccine. 
Of the four VLP vaccines currently on the mar‑
ket, those for HBV and HPV are the best described 
(Buonaguro, et al., 2011) (Table II). The HBV VLPs 
contains virus surface antigen (HBsAg) and was the 
first VLPs vaccine to be generated (in 1980s) (Zucker‑
man, 1980, Zuckerman, 1985). Its successful produc‑
tion was reported in mammalian (Aden et al., 1979) 
yeast (Valenzuela et al., 1982), insect (Takehara et al., 
1988), and plant (Mason et al., 1992) expression sys‑
tems. Afterwards, HBV VLPs based on the core antigen 
(HBcAg‑VLPs) were also developed. However, these 
are still in the preclinical stage of evaluation and are 
mainly used as a platform for the presentation of for‑
eign epitopes from heterologous pathogens or tumor 
antigens (Kazaks et al., 2008). 
For HPV prophylaxis, VLPs are formed with L1 
HPV capsid protein overexpressed in S. cervisiae or 
T. ni is used to prepare the licensed vaccine, but HPV 
VLP formation was demonstrated also in P. pastoris 
(Hanumantha Rao et al., 2011) and plant cells (Deleré 
et al., 2014; Scotti and Rybicki, 2013). The HPV vaccine, 
which showed 98% efficacy in protecting individuals 
from HPV16/18 infections (which are responsible for 
more than 70% of invasive cervical cancers) became 
a milestone in cancer prevention (Deleré, et al., 2014).
As for the influenza vaccine, which must be pro‑
duced de novo each year, development, production, and 
approval times are critical. Conventional licensed influ‑
enza vaccines are prepared from embryonated chicken 
eggs, inoculated individually with virus strains selected 
for the season. Viruses are harvested from the allantoic 
fluid, chemically inactivated, concentrated, and purified 
to remove non‑viral protein contaminants. The whole 
production process takes several months and is often 
hampered by the poor growth yield of some influenza 
strains (Reperant et al., 2014). Therefore, the VLP‑based 
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vaccines which are faster, cheaper and safer to obtain, 
represent an attractive alternative (Fig. 2). An influenza 
VLPs vaccine produced in insect cells was approved 
in US in 2013, but other influenza VLP candidates, 
produced in plant cells, bacteria, or cell‑free systems, 
demonstrated as effective and safe and are currently in 
clinical trials (Chroboczek et al., 2014; Lee et al., 2014).
Other VLP vaccines that are currently in clinical 
trials utilize proteins from different viruses, including 
respiratory syncytial virus (Glenn et al., 2013), Norwalk 
virus (Herbst‑Kralovetz et al., 2010), human parvovi‑
rus B19 (Chandramouli et al., 2013), and P. falciparum 
(chimeric VLP) (Agnandji et al., 2012). VLPs vaccine 
candidates for human use, that were shown to be immu‑
nogenic in animal models but are still under preclinical 
investigation include: human immunodeficiency virus 
(HIV‑1), severe acute respiratory syndrome coronavi‑
rus (SARS‑CoV), hepatitis C virus (HCV), RSV, rota‑
virus (RV), dengue (DENV), rabies (Kushnir, et al., 
2012; Roldão et al., 2010), and others.
Veterinary vaccinology is a distinct, broad field, 
which will not be discussed in this review, but VLPs 
HBV (HBsAg) Hepatitis B Bacteria On market
 (Engerix­B, Recombivax HB, Yeast (GlaxoSmithKline, Merck,
 GenHevacB, Euvax B, others…) Insect Sanofi‑Pasteur, LG Life Sciences)
  Plant 
HPV (L1) Human papilloma virus Yeast On market
 (Gardasil, Cervarix) Insect (Merck, GlaxoSmithKline)
HEV (HE antigen) Hepatitis E (Hecolin) Bacteria On market (Xiamen Innovax Biotech )
Influenza virus Influenza virus (Flublok) Insect On market USA (Protein Science Corporation)
Influenza  Plant, insect
RSV  Insect
Norovirus  Cell free, insect, plant
HIV  Yeast
Parvovirus B19  Insect Clinical studies
Rabies  Plant
Malaria (chimeric) Malarivax Bacteria
Table II
VLP vaccines and vaccine candidates.
VLP (protein) Vaccine Expression system Development status
Fig. 2. Comparison of vaccine production using traditional virus cultures (panel A) and VLPs (panel B).
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have also been investigated as vaccine candidates for 
animal use (Liu et al., 2012).
As mentioned above, the plasticity of VLPs enables 
the formulation of chimeric vaccines loaded with hete‑ 
rologous antigens. This can be achieved either by co‑
expression of structural proteins of different viruses or 
by gene fusion, and results in foreign epitopes displayed 
on the external surface of the VLPs. The first strategy 
can be illustrated by the SARS‑CoV VLP, where SARS 
spike protein is incorporated into an influenza matrix 1 
protein scaffold, overcoming the problem of low yield 
in the production of the native SARS VLPs (Liu et al., 
2011). Using the second approach the synthesis of par‑
ticles that do not form native VLPs at all, becomes feasi‑
ble. An anti‑malaria vaccine, currently in clinical trials, 
is an example of a VLP displaying a non‑viral antigen 
(S protein of P. falciparum) that is expressed as a fusion 
partner with HBsAg (Agnandji et al., 2012).
Alternatively, VLPs may be engineered to modulate 
the immune response by conjunction of adjuvants or 
stimulatory molecules such as Toll‑like receptors (TLR) 
ligands and T‑cell epitopes. For example, VLPs contain‑
ing CpG motifs, a ligand for TLR‑9, have significantly 
improved anti‑HPV VLP humoral responses in the 
peripheral blood and in genital mucosal secretions in 
animal models (Gerber et al., 2001; Hjelm et al., 2014). 
Similarly, HIV VLPs equipped with cholera toxin subu‑
nit B showed increased stimulation of mucosal cellu‑
lar response (Kang et al., 2003; Ludwig and Wagner, 
2007). Another VLP developed to co‑deliver interleu‑
kin‑2 resulted in robust cytotoxic T‑lymphocyte activa‑
tion (Juarez et al., 2012; Oh et al., 2004). In addition to 
enhancing the immune response, including immunity 
potentiators, improves the pharmaco‑kinetic profile of, 
VLPs reducing nonspecific binding to serum proteins. 
Vaccines for non-infectious diseases
Vaccines for non‑infectious diseases are an interest‑
ing application for chimeric VLPs, which are designed 
to induce specific antibodies directed against self‑anti‑
gens and thus boost humoral immunity. These VLPs 
carry antigens typical for cancer (melanoma), neurode‑
generative diseases (Alzheimer’s disease), autoimmune 
diseases (allergic rhinoconjunctivitis and asthma) and 
other disorders (Table  III). Most therapeutic VLP 
vaccines are based on the bacteriophage Qβ, which is 
highly expressed in E. coli, enabling the development of 
an economical large‑scale production process. Impor‑
tantly, during self‑assembly, bacteriophage Qβ packages 
host‑derived RNA (the natural ligand for TLR7 and 
TLR8), thus activating antigen‑specific IgG2a responses 
(Bachmann and Jennings, 2011).
VLPs as delivery platforms
The remarkable and unique advantage of VLPs as 
delivery vehicles is theirs specificity, which results from 
the receptor‑mediated transduction mechanism. Simi‑
lar to native viruses, most VLPs target and penetrate 
different cell types depending on receptors exposed at 
their surface. As a consequence, the diverse tropisms 
of parental viruses provide a range of natural target‑
ing capabilities for VLPs, without the need for further 
modifications (Seow and Wood, 2009).
Decorating VLPs with foreign molecules may be 
achieved by various means, including genetic manipu‑
lation, non‑covalent interactions, or chemical coupling 
of different compounds. Physical encapsulation of 
organic and non‑organic moieties has been described 
as well and consists of the disassembly of purified 
VLPs (by osmotic shock, use of chelating agents, or 
varying the pH) and reassembly in the presence of the 
desired molecule. Table IV summarizes VLPs packag‑
ing methods and examples of cargo molecules that have 
been successfully delivered to target cells.
Delivering drugs into target cells is particularly 
important for anti‑proliferation chemotherapeutics, 
where systemic administration causes undesired side‑
effects. Therefore, specific carriers, such as VLPs, are 
of significant interest in this field. Successful transfer 
of VLPs packaged with anticancer agents was described 
for bleomycin (BLM) and doxorubicin (DOX). Both 
conjugates were chemically coupled to VLPs (BLM to 
adenoviral VLPs and DOX to RV VLPs) and have dem‑
Qβ‑amyloid β epitope Alzheimer disease Phase 2 (Chackerian et al., 2006)
Qβ‑CpG oligodeoxynucleotides Allergic rhinoconjunctivitis and asthma Phase 2 (Senti et al., 2009)
Qβ‑IL1β protein Diabetes mellitus type 2 Phase 2 (Bachmann and Jennings, 2011)
Qβ‑angiotensin II epitope hypertension Phase 2 (Tissot et al., 2008)
Qβ‑melan A peptide Malignant melanoma Phase 2 (Braun et al., 2012)
Qβ‑nicotine Nicotine addiction Phase 2 (Maurer et al., 2005)
HPV‑TNFα Arthritis – (Chackerian et al., 2001)
Table III
Therapeutic VLP vaccines.
VLP Therapeutic target Status Ref
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onstrated improved drug bioavailability and growth 
inhibition of targeted cancer cells (Zhao et al., 2011; 
Zochowska et al., 2009). 
The ability to bind nucleic acids is common for viral 
structural proteins and is used to pack oligonucleotides 
and plasmids (as well as other negatively charged sub‑
stances) into VLPs (Zeltins, 2013). DNA‑loaded VLPs 
were developed for gene therapy and aroused great 
hope as potential specific carriers of nucleic acids (Petry 
et al., 2003, Ramqvist et al., 2007). Successful expression 
of β‑galactosidase, encoded by a plasmid delivered by 
a polyomavirus VP1 VLP to different tissues, demon‑
strated the feasibility of the VLP‑mediated gene therapy 
concept (May et al., 2002). Up to 17 kb of DNA may 
be packaged into an SV40 polyoma VLP, as reported 
by Kimchi‑Sarfaty (Kimchi‑Sarfaty et al., 2003), but the 
theoretical capacity of larger VLPs is probably higher. In 
subsequent years, the increasing interest in use of modi‑
fied small interfering RNAs as therapeutics resulted in 
further studies on VLPs as delivery vessels for these 
molecules (Seow and Wood, 2009). For example, treat‑
ment of lupus‑prone mice with bacteriophage MS2 
VLPs loaded with miR‑146a miRNA –  a  recognized 
gene silencer – inhibited the production of auto‑anti‑
bodies and inflammatory cytokines (Pan et al., 2012). 
Protein delivery by VLPs has been described for 
heterologous antigens, antibodies, cytokines, enzymes, 
and reporter proteins such as green fluorescent protein 
(GFP) or maltose binding protein (MBP). Cargo pro‑
teins are usually tethered to the external surface of the 
VLP by genetic fusion to structural VLP protein or by 
exploiting natural interactions between the transported 
protein and structural proteins present in VLPs (anti‑
gen‑antibody interactions, ligand‑receptor interactions, 
inter‑domain interactions etc.). Conjunction of Her‑
ceptin, an antibody directed against a mutated version 
of the tyrosine kinase receptor HER2 to the polyoma 
VLP is a good illustration of the potential use of VLPs 
in directed cancer immunotherapy (Gleiter and Lilie, 
2003). Another example of a protein targeting ligand is 
epidermal growth factor (EGF), which was incorporated 
into SV40 polyoma VLPs, that selectively transduced 
cells overexpressing the EGF receptor (Kitai et al., 2011).
Labeling VLPs with fluorophores is another way of 
tethering foreign substances to these nanovectors but 
also a powerful research tool. Fluorescent VLPs can be 
traced within host cell, tissue, or organism. Viral parti‑
cles can be labeled by covalent or non‑covalent chemical 
methods or by fusion of fluorophores to proteins inte‑
grated into the viral particle. Chemical methods consist 
of inserting fluorescent dyes into the viral membrane. 
Alternatively, attachment of streptavidin‑coupled fluo‑
rophores can be achieved by biotinylating target struc‑
tures of interest (Wojta‑Stremayr and Pickl, 2013).
The feasibility of encapsulating metal nanoparticles 
within the VLP cavity was shown by packaging adeno‑
virus (AdV) VLPs with nanogold molecules (Fuschi‑
otti et al., 2006). Recently, an interesting application 
Proteins
Antibody PyV genetic fusion to VLP protein (Gleiter and Lilie, 2003)
GFP RV genetic fusion to VLP protein (Charpilienne et al., 2001)
MBP tag AdV protein adaptor (Garcel et al., 2006)
Enzyme AdV biotin‑streptavidin interaction (Fender et al., 2003)
Cytokine (IL‑2) HPV encapsulation (Oh, et al., 2004)
Nucleic acids
Plasmid DNA HPV encapsulation (Malboeuf et al., 2007)
RNAi PyV encapsulation (Kimchi‑Sarfaty, et al., 2003)
Metal nanoparticles
Gold AdV encapsulation (Fuschiotti, et al., 2006)
Magnetic nanoparticles HBV encapsulation (Pushko et al., 2013)
Fluorophore
Carboxyfluorescein HPV chemical coupling (Bergsdorf et al., 2003)
Propidium iodode PyV chemical coupling (Goldmann et al., 2000)
Quantum dots PyV chemical coupling (Wojta‑Stremayr and Pickl, 2013)
Drugs
Bleomycin AdV chemical coupling (Zochowska, et al., 2009)
Doxorubicin  RV chemical coupling (Zhao, et al., 2011)
Table IV
VLPs as delivery platforms for foreign molecules (PyV: Polyoma virus).
Cargo VLP Attachment Ref.
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for another functionalized VLPs has been described 
providing proof of concept for the use of VLPs for 
diagnostic purposes. Cowpea chlorotic mottle virus 
(CCMV) VLP loaded with Gd3+ ions or HBcAg‑VLPs 
loaded with Fe3O4 serve as paramagnetic high contrast 
agents for magnetic resonance imaging (Mateu, 2011, 
Shen et al., 2014). 
Even though VLPs seem to be universal delivery 
platforms, they do possess several limitations, especially 
to their use as gene or drug carriers. The most chal‑
lenging problem concerns the pre‑existing immunity 
in most individuals for common viruses. A solution 
proposed to overcome undesirable immunogenic‑
ity of VLPs consists of modifying them with immune 
masking agents, such as polyethylene glycol (PEG), 
which has been shown to suppress the primary anti‑
body response (Jain and Jain, 2008). Another concern 
that must be kept in mind is that like any virus‑based 
treatment, VLPs are not suitable for repetitive admin‑
istration. The exception here is cancer immunotherapy, 
where the goal is to stimulate tumor recognition in an 
escalating manner. Initial enthusiasm for VLP‑medi‑
ated gene therapy has been tempered by the lack of 
large‑scale methods for adequate internalization and 
proper release of the desired nucleic acid, and further 
research will be necessary to overcome this problem 
(Pattenden et al., 2005). It is also worth noting, that the 
different mechanism of assembly of non‑enveloped and 
enveloped VLPs impede in vitro encapsulation of for‑
eign molecules in the latter.
Concluding remarks
Virus‑like particles have been produced for a wide 
range of taxonomically and structurally distinct viruses 
and have unique advantages in terms of construction 
flexibility. Moreover, their versatility relies on their 
unique structural diversity and tailorable functional‑
ity. Potential uses of VLPs include vaccine production, 
vectors for gene therapy and targeted drug delivery, and 
molecular imaging tools (Fig. 3). However, translation 
from preclinical research to licensed products requires 
extensive studies in animal models that remain to be 
completed. Firstly, effective and scalable loading of 
cargo onto VLPs vectors requires further investigation. 
Futhermore, careful evaluation of the toxicity, biodistri‑
bution, stability in vivo, and clearance of VLPs will be 
crucial in order for these nanocarriers to be considered 
for medical use.
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Fig. 3. Diagram showing possible VLP applications.
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